0:000:00
<p>A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7</strong></p> <ul> <li><strong>Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837</strong></li> </ul> <p><strong>II KP Vaccinate Trial</strong></p> <ul> <li><strong>KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208</strong></li> <li><strong>IAMI trial https://www.ahajournals.org/doi/10....